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Abstract
Objective—To examine long-term prognosis of a zero coronary artery calcium (CAC) score 
among asymptomatic individuals and its associated warranty period.
Background—Emerging evidence supports CAC=0 as a favorable cardiovascular short-to-
intermediate term prognostic factor.
Address for correspondence: James K. Min, MD, FACC, 413 E. 69th Street, Suite 108, Dalio Institute of Cardiovascular Imaging, 
New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, NY 10021, Phone: 646-962-6192, Fax: 
646-962-0129, jkm2001@med.cornell.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2016 August 01.
Published in final edited form as:
JACC Cardiovasc Imaging. 2015 August ; 8(8): 900–909. doi:10.1016/j.jcmg.2015.01.025.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Methods—9715 individuals undergoing CAC imaging were stratified by age, Framingham risk 
score (FRS) and Adult Treatment Panel III (NCEP ATP III) categories and followed for a mean of 
14.6 (12.9–16.8) years. Cox regression, area under the receiver operating characteristic curve 
(AUC) and net reclassification information (NRI) were used to assess all-cause mortality, 
discrimination and reclassification of CAC=0 compared with FRS and NCEP ATP III, 
respectively. A warranty period was pre-defined as <1% annual mortality rate. Vascular age was 
estimated by linear regression.
Results—Among 4864 individuals with baseline CAC=0 (mean age 52.1±10.8 years; 57.9% 
male), 229 deaths occurred. The warranty period of CAC=0 was almost 15 years for individuals at 
low and intermediate risk with no significant differences regarding age and gender. CAC=0 was 
associated with a vascular age of 1, 10, 20, and 30 years below chronologic age for individuals 
between 50–59, 60–69, 70–79, and ≥80 years, respectively. CAC score was the strongest predictor 
of death (HR 2.67, 95% CI 2.29–3.11) that enabled discrimination and consistent reclassification 
beyond FRS (AUC 0.71 vs. 0.64, p<0.001) and NCEP ATP III (AUC 0.72 vs. 0.64, p<0.001).
Conclusions—CAC=0 confers a 15-year warranty period against mortality among individuals at 
low-to-intermediate risk, which is unaffected by age or gender. Furthermore, in individuals 
considered at high-risk by clinical risk scores the presence of CAC=0 confers better survival than 
in individuals at low-to-intermediate risk but with any CAC.
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INTRODUCTION
In population-based studies, coronary artery calcium (CAC) scoring by computed 
tomography (CT) accurately stratifies cardiovascular risk for asymptomatic individuals.1–5 
Notably, CAC presence,6,7 extent,8 and progression9,10 have been shown to be associated 
with major adverse cardiovascular events4,6–10 and death,3,4,3,10–15 independent of 
conventional risk factors. Conversely, a favorable prognosis has been observed in the 
absence of CAC.16–18 The majority of these studies have evaluated the salutary effect of a 
CAC = 0 in cohorts with up to 5 years of follow-up, a time point where a generally low 
number of incident adverse clinical events has occurred. However, whether CAC = 0 confers 
long-term protection against poor survival incremental and independent to clinical risk 
scoring, and its associated “warranty period,” remains to be elucidated. Further, several 
recent studies have highlighted the important distinction between chronologic and “vascular 
age”, the latter of which adjusts an individual’s risk of mortality based upon the level of 
CAC.19,20 To date, the long-term impact of CAC = 0 for the estimation of vascular age 
versus the chronologic age is unknown. Thus, in the present study, we set out to determine 
the long-term prognosis associated with a CAC = 0, comparing the prognosis of CAC = 0 to 
the prognosis obtained by the current clinical prediction models such as the Framingham 
risk (FRS) and the Adult Treatment Panel III (NCEP ATP III) scores, quantifying the 
“warranty period” for CAC=0 and lastly, examining the association of CAC = 0 to 
chronologic versus vascular age.
Valenti et al. Page 2
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
METHODS
Study population
The study cohort comprised of 9715 consecutive asymptomatic individuals without known 
coronary artery disease (CAD). All individuals were referred by their physicians for CAD 
evaluation and underwent CAC testing electron beam computed tomography (EBCT) at a 
single site. All individuals provided informed consent to undergo EBCT and the study 
received approval from the Human Investigations Committee.
Risk factor collection
All study participants were queried for the following baseline cardiovascular risk factors: 1) 
cigarette smoking was considered to be present if a subject was an active smoker at the time 
of scanning; 2) dyslipidemia was considered to be present for any individual reporting a 
history of high total cholesterol, high low-density lipoprotein cholesterol, low high-density 
lipoprotein cholesterol, high triglycerides, or current use of lipid-lowering therapy; 3) 
diabetes was defined as baseline use of anti-diabetic medication or had a history of elevated 
blood glucose measurement of >126 mg/dl use; 4) hypertension was defined as a self-
reported history of high blood pressure or the use of antihypertensive medication; and 5) 
family history of premature CAD was determined by asking individuals whether any 
member of their immediate family (i.e., parents or siblings) had a history of fatal or nonfatal 
myocardial infarction and/or coronary revascularization in a male relative <55 years or a 
female relative <65 years.
EBCT screening protocol
Subjects underwent EBCT on either a C-100 or C-150 Ultrafast CT scanner (Imatron, South 
San Francisco, California). With a tomographic slice thickness of 3 mm, a total of 
approximately 40 sections were obtained beginning at the level of the carina and proceeding 
caudally to the level of the diaphragm. Images were obtained with a 100 ms / slice scanning 
time, with image acquisition electrocardiographically triggered at 60% to 80% of the R-R 
interval. A calcified lesion was defined as >3 contiguous pixels with a peak attenuation of at 
least 130 Hounsfield units. Each lesion was then scored using the method developed by 
Agatston et al.21 (Agatston units). The estimated radiation dose was approximately 1 mSv.
Study outcome
The primary endpoint of this study was death from all causes. Ascertainment of mortality 
status was conducted by individuals masked to baseline historical data and EBCT results, 
and was verified using the Social Security Death Index. The United States Social Security 
Death Index is a national registry of all deaths that have occurred in the United States, 
allowing for 100% mortality ascertainment among study participants.
Definition of warranty period
In accordance with societal guidelines, an annual mortality rate below 1% was employed to 
define individuals as low risk.22 For the purposes of this study, a warranty period was 
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defined as the time an individual remained within the low risk category; conversely, 
reported values of annual mortality rate above 1% signified warranty period cessation.
Statistical methods
Categorical variables are presented as counts with proportions and continuous variables as 
mean ± SD. The Pearson chi-square test was employed for comparison of categorical 
variables. Between-group comparisons for continuous variables were computed using the 
independent samples t-test or the Mann-Whitney U test as appropriate. Multivariable Cox 
proportional hazard regression models reporting hazard ratios (HR) with 95% confidence 
intervals (95% CI) were performed to examine and compare the risk of death from all-
causes among individuals. The latter model adjusted for age, gender, cigarette smoking, and 
cardiovascular morbidities including diabetes, hypertension, dyslipidemia, and family 
history of premature CAD.
The relationship between a CAC = 0 and mortality was determined as a function of varying 
cardiovascular risk as determined by widely employed clinical risk scores. Cox regression 
models stratified individuals according to pre-defined categories as quantified by low 
(<10%), intermediate (10% to 20%), and high (>20%) risk using 10-year FRS and NCEP 
ATP III scores.3,23 Linear regression models were used to estimate the vascular age using 
patients’ chronologic age as the dependent variable and the CAC score as the independent 
variable.19 Group differences between vascular age and chronologic age were plotted. 
Additionally, for each corresponding category of age, annual mortality rates were calculated. 
Discriminatory power of CAC over FRS and NCEP ATP III was evaluated using areas 
under the receiver operator characteristic curve (AUC)24 and compared using the DeLong 
method.25 Reclassification was determined using category-free net reclassification 
improvement (NRI) indices.26 Statistical analyses were performed using STATA version 
12.0 (StataCorp LP, College Station, TX, USA) and SAS version 9.3 (SAS Institute Inc., 
Cary, NC). A two-tailed P-value <0.05 was considered statistically significant.
RESULTS
Study population
Of 9715 individuals (mean age 53.4±10.5, 59.3% male) undergoing CAC screening, 4864 
(mean age 52.1±10.8 years; 57.9% male) had a CAC = 0. At a follow-up mean of 14.6 
(12.9–16.8) years, there were 936 (9.6%) deaths in the study population. Of deaths, 229 
(4.7%) and 707 (14.6%) occurred among individuals with a CAC = 0 and CAC > 0, 
respectively. Demographic characteristics of the study sample are summarized in Table 1. 
Overall, prevalent hypertension, dyslipidemia, smoking status, diabetes, family history of 
premature coronary artery disease (CAD), FRS and NCEP ATP III, were higher among 
individuals with CAC > 0 versus CAC = 0. Survival was higher for CAC = 0 (95.1% vs. 
83.7%, P<0.001).
CAC and long-term prognosis
In multivariable analyses, CAC > 0 was the strongest predictor of death in overall 
population beyond individual cardiovascular risk factors, FRS and NCEP ATP III and it was 
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associated with a nearly 3-fold (HR 2.67, 95% CI 2.29–3.11) risk of death (Table 2). The 
presence of diabetes (HR 2.53, 95% CI 1.74–3.69), active smoking (HR 1.95, 95% CI 1.50–
2.53), and hypertension (HR 1.58, 95% CI 1.21– 2.06) were associated with increased risk 
of mortality among individuals with CAC = 0. In the presence of any CAC, the risk 
increased proportionally with the severity in the CAC score but independently of the 
Framingham Risk Score (FRS) and the risk model provided by the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATPIII) (Table 3). Men and women 
showed similar survival and mortality risk either in the presence or in the absence of CAC 
(Figure 1 A and B, Supplemental).
Warranty period of CAC = 0
Figure 1 describes the 15-year cumulative mortality rate among all study individuals, and 
those considered low risk by FRS, NCEP ATP III, absence of CAD risk factors and CAC = 
0; individuals with CAC = 0 experienced the lowest rates of mortality. Independent of FRS 
(Figure 2A) or NCEP ATP III class (Figure 2B), a CAC = 0 was associated with a favorable 
prognosis. Risk of all-cause mortality was higher among individuals with CAC > 0 and low 
cardiovascular risk (FRS = HR 3.3, 95% CI 2.49–4.32; NCEP ATP III = HR 3.09, 95% CI 
2.45–3.90), as compared with those with CAC = 0 and high cardiovascular risk (FRS = HR 
2.8, 95% CI 2.05–3.92; NCEP ATP III = HR 2.94, 95% CI 2.15 –4.01).
Figure 3 shows the annual mortality rates for individuals with CAC = 0 and CAC > 0. A 
CAC = 0 was associated with >15 year warranty period, with the observed rate of mortality 
remaining <1% during the entirety of follow-up. Mortality rates in individuals with CAC = 0 
were non-linear in nature, with a lower event rate (mean 0.3% ± 0.08% events/year) during 
the initial 12 years that accelerated during the 13th (0.4% events/year) and 14th (0.58% 
events/year) years. Figure 4 depicts the warranty period of a CAC = 0 in select subgroups. 
CAC = 0 was associated with a warranty period of 15 years for individuals below the age of 
60 years, with no apparent disparity among genders. The observed duration of the warranty 
period of a CAC = 0 was slightly shorter for those ≥60 years, and ceased after 14 years of 
follow-up. Despite CAC = 0, individuals considered at high cardiovascular risk by clinical 
risk, experienced a significantly shorter warranty period (5–6 years) than individuals at low-
to-intermediate risk. However, the warranty period for high-risk categories with CAC = 0 
was even longer than individuals at low-to-intermediate risk with a CAC > 0.
Vascular age in individuals with CAC = 0
A CAC = 0 was associated with a lower vascular versus chronologic age, a finding more 
pronounced for individuals of increasing age and for men versus women (Figure 5 A). As an 
example, the vascular age afforded by CAC=0 for a man ≥80 years of age was equivalent to 
the chronologic age of a 50 year old man within the general population. The annual 
mortality rate observed for patients with CAC=0 was lower than the equivalent category of 
chronologic age, in the general population (Figure 5 B).
Incremental predictive value of CAC for individuals with CAC > 0
Compared with the base models of FRS or NCEP ATP III alone, discrimination improved 
significantly (Area under the receiver operating characteristics curve [AUC] 0.71 versus 
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0.64, and 0.72 versus 0.64 for FRS and NCEP ATP III, respectively, p<0.001 for both) when 
CAC was added to the FRS or NCEP ATP III. The addition of CAC to the FRS or NCEP 
ATP III also resulted in significant reclassification of events and non-events among 
individuals (both P<0.001). Irrespective of risk prediction category, CAC improved risk 
classification for those at risk versus not at risk for incident mortality (P<0.001) (Table 4).
DISCUSSION
In the present study, we extensively examined the long-term prognostic utility of CAC 
imaging in a large cohort of asymptomatic individuals with 15 years of follow-up. We 
observed the presence of CAC to be a strong predictor of incident mortality, even when 
considering robust clinical risk scores by Framingham or NCEP ATP III methods. 
Importantly, we identified a very low risk state that lasted for the duration of follow-up. The 
low risk associated with a CAC = 0 persisted to more than 15 years for individuals <60 
years of age, and to 14 years for individuals ≥60 years of age, with no apparent disparity 
among genders. Importantly, the warranty period conferred by CAC = 0 was similar for 
individuals of low- or intermediate- clinical risk by FRS and NCEP ATP III. Individuals 
considered at high clinical risk but with CAC = 0, had a higher warranty period than those at 
low- or intermediate-clinical risk with any CAC. Conversely, the presence and severity of 
CAC were independently associated with increased mortality risk by the FRS and the NCEP 
ATP III. Finally, a CAC = 0 was associated with a vascular age that was approximately 30 
years lower than chronologic age for older individuals and was associated with a significant 
lower annual mortality rate than the equivalent chronologic age category. Taken together, 
these findings indicate the robustness of a CAC = 0 to identify individuals disposed to a 
particularly propitious outcome, and may be useful as an adjunctive measure to everyday 
clinical risk assessment.
The present findings support as well as expand the extant literature16–18 that have 
investigated the incremental utility of CAC imaging for the evaluation of asymptomatic 
individuals at risk for cardiovascular disease. The high prevalence of a CAC = 0 in 
individuals classified as intermediate-to-high risk based by clinical risk scores suggests that 
such scores are highly imperfect in identifying persons at elevated risk of mortality.27,28 To 
this end, the present study detected a significant higher risk of mortality for individuals with 
a CAC > 0 who were considered low risk by clinical score, with respect to those with CAC 
= 0 who were considered intermediate or high risk. Yet, while robust in risk prediction, a 
CAC = 0 was significantly less effective at conferring a long-term warranty for individuals 
considered high risk by FRS and NCEP ATP III. Thus, while current guidelines support the 
use of CAC imaging among asymptomatic individuals at intermediate cardiovascular risk,29 
the present study suggests a long-term incremental value of CAC>0 for individuals initially 
considered to be at low risk but who are subsequently reclassified as at high cardiovascular 
risk based on CAC testing. Whether there is a clinical benefit of identification of a shorter 
warranty period of 5–6 years for individuals considered to be high risk by FRS or NCEP 
ATP III requires further examination in health outcomes studies.
In this study, the beneficial prognosis of a CAC = 0 is further supported by evidence of a 
vascular age reduction compared to chronologic age, with an associated improvement in 
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prognosis. Though it is generally accepted that the prevalence of coronary plaque burden 
and mortality rate increase with advancing age, the presence of a CAC = 0 may be effective 
as an index of “vascular youth.”19,20 These study findings validate the concept of “vascular 
youth” as determined by a CAC = 0, wherein individuals >50 years of age may be reassured 
that their coronary vasculature is “younger” than those of their peers, and that this 
auspicious finding confers a good long-term prognosis.
These study findings are of high clinical importance. Given the 15-year warranty of a CAC 
= 0 for individuals at low-to-intermediate clinical risk irrespective of gender and age—a 
period only mildly attenuated for older patients ≥60 years—the use of CAC may be 
instrumental for avoiding unnecessary testing even amongst individuals generally 
considered at higher peril for unheralded adverse clinical events. While some may speculate 
that the prognostic security of a CAC = 0 may offer an opportunity to attenuate medical 
therapies, our study findings apply only to coronary rather than cardiovascular assessment in 
other vascular beds such as the carotid circulation. Thus, the current results should not be 
interpreted as supporting a practice of therapy diminution or cessation as this matter is 
beyond the scope of our investigation. Future large-scale studies examining this concept 
should first be performed.
This study is not without limitations. Despite the large study sample-size, long-term follow-
up, and prospective evaluation of study individuals, the single-center design of the present 
study may have introduced unobserved biases related to selection. In this regard, future 
population-based studies with long-term follow-up will be important to help confirm the 
present study findings. Further, CAC was performed only once for the present study and the 
rates of CAC progression were not accounted in the determination of the CAC = 0 warranty 
period. It remains conceivable that individuals who experience accelerated or retarded CAC 
progression may possess different warranty periods, and future studies should be performed 
to examine this. Also, the long-term mitigating effects of medical therapy and lifestyle 
modification and how they might influence the relationship between CAC and mortality 
cannot be accounted for in this investigation. Hence, forthcoming studies that utilize time-
varying clinical measures in patients with known CAC values are now needed. Finally, we 
employed all-cause mortality as the primary endpoint for this study and thus, our analysis is 
unable to offer information regarding the impact of CAC specifically on cardiovascular 
morbidity and mortality, such as that used for the 2013 ACC/AHA guidelines.30 However, 
the use of mortality disentangles the study from ascertainment or misclassification bias, and 
represents the hardest end-point to be evaluated in population studies. Indeed, the lack 
atherosclerotic cardiovascular disease-specific mortality in our study may have only 
contributed to an underestimation of the real impact of CAC on cardiovascular risk.31
CONCLUSION
A CAC = 0 confers a 15 year warranty period against mortality that is unaffected by age or 
gender, with a significant reduction in vascular over chronologic age. These findings are 
consistent in individuals with low and intermediate risk. In individuals considered at high 
risk by clinical risk scores the presence of CAC = 0 confers a longer warranty period 
compared to individuals at low- or intermediate- risk in presence of any CAC.
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PERSPECTIVES
Competency in Medical Knowledge
Traditionally, coronary artery disease (CAD) has been assessed in terms of measures of 
stenosis severity. Characterization of atherosclerotic plaque characteristics, in addition to 
stenosis severity, may improve the diagnosis and prognostic risk assessment of patients 
with CAD. Features suggesting high-risk seen with computed tomography include 
atherosclerotic plaque as well as coronary artery calcification volume and density and 
others, such as low attenuation plaque, positive remodeling and spotty calcification. 
Conversely, absence of coronary artery calcium is protective against coronary events 
over long period of follow up.
Translational Outlook
Additional clinical studies are required to determine the optimal methods for reporting 
CAD measures of stenosis or atherosclerosis, as well as to determine their prognostic 
implications and optimal approaches to therapy.
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Figure 1. 15-year cumulative mortality rate for the study period
15-year cumulative mortality rate according to the overall study population and individuals 
considered low risk by Framingham Risk (blue line), National Cholesterol Education 
Program Adult Treatment Panel III (purple line), the absence of any CAD risk factor (yellow 
line), and CAC = 0 (green line).
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Figure 2. Hazard ratios for risk of all-cause mortality
Hazard ratios for risk of all-cause mortality among individuals with and without coronary 
artery calcification according to: (A) Framingham Risk Score, and (B) National Cholesterol 
Education Program Adult Treatment Panel III.
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Figure 3. Annual mortality rate during the study period
An annual mortality rate below 1% was employed in order to classify individuals at low-risk 
of cardiovascular events.
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Figure 4. Observed warranty period for absence of CAC compared with the presence of CAC
Observed warranty period (time to exceed 1% risk) for a CAC = 0 compared with the 
presence of any coronary artery calcium across 15 years of follow-up among 9715 
asymptomatic individuals stratified by coronary artery calcium score, age, gender, 
Framingham risk score (FRS) and National Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III).
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Figure 5. Differences between chronologic and vascular age
(A) Differences between chronologic versus vascular age in patients with zero coronary 
artery calcium score and (B) the corresponding annual mortality rate.
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Table 1
Clinical characteristics of the study sample
(Risk Factor Cohort) Overall(N=9715)
CAC=0
(N=4864)
CAC>0
(N=4851) P value
Mean Age ± SD 53.4±10.5 52.1±10.8 54.6±10.0 <0.001
Male Gender 59.3% 57.9% 60.8% 0.003
Hypertension 43.4% 36.8% 50.1% <0.001
Dyslipidemia 62.6% 57.8% 67.3% <0.001
Diabetes 8.3% 5.7% 11.0% <0.001
Smoking 39.3% 33.6% 45.0% <0.001
Family History of
Premature CAD (%) 68.7 69.7 67.7 0.03
Death 936 (9.6%) 229 (4.7%) 707 (14.6%) <0.001
15 year survival 89.6% 95.1% 83.7% <0.001
FRS23 <0.001
  Low (<10%) 40.7% 50.0% 31.4%
  Intermediate (10–20%) 41.3% 37.3% 45.3%
  High (>20%) 18.0% 12.7% 23.3%
NCEP ATP III3 <0.001
  Low (<10%) 53.4% 62.9% 43.8%
  Intermediate (10–20%) 27.7% 23.7% 31.8%
  High (>20%) or DM 18.9% 13.4% 24.4%
Abbreviations: CAC, coronary artery calcium; DM, diabetes mellitus; FRS, Framingham Risk Score; NCEP ATP III, National Cholesterol 
Education Program Adult Treatment Panel III.
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Table 3
Hazard Ratio analysis of 15-years all-causes mortality in asymptomatic individuals according to the coronary 
artery calcification score.
Overall
(N=9715)
Univariable Multivariable
HR Adjusted for FRS Adjusted for NCEP-ATPIII
CAC 0 1.00 (ref) 1.00 (ref) 1.00 (ref)
CAC 1–99 2.21 (1.86–2.64) p<0.001 2.08 (1.74– 2.48) p<0.001 2.03 (1.70–2.42) p<0.001
CAC 100–399 3.85 (3.19 –4.66) p<0.001 3.42 (2.83– 4.14) p<0.001 3.32 (2.74 –4.02) p<0.001
CAC 400–999 5.98 (4.84–7.39) p<0.001 4.93 (3.98–6.12) p<0.001 4.81 (3.87 – 5.97) p<0.001
CAC ≥1000 8.66 (6.79–11.05) p<0.001 6.79 (5.29–8.72) p<0.001 6.99 (5.46– 8.95) p<0.001
Abbreviations: CAC, coronary artery calcification; FRS, Framingham risk score; NCEP-ATP III, National Cholesterol Education Program Adult 
Treatment Panel III. 3
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Valenti et al. Page 21
Ta
bl
e 
4
N
et
 re
cl
as
sif
ic
at
io
n 
im
pr
ov
em
en
t w
ith
 th
e 
ad
di
tio
n 
of
 c
or
on
ar
y 
ar
te
ry
 c
al
ci
um
 sc
or
in
g 
to
 a
 m
od
el
 in
cl
ud
in
g 
th
e 
Fr
am
in
gh
am
 R
isk
 S
co
re
 o
r N
at
io
na
l 
Ch
ol
es
te
ro
l E
du
ca
tio
n 
Pr
og
ra
m
 A
du
lt 
Tr
ea
tm
en
t P
an
el
 II
I s
co
re
N
R
I
95
%
 C
I
P-
V
al
ue
%
Ev
en
ts
co
rr
ec
tly
re
cl
as
sif
ie
d
Ev
en
t
P-
V
al
ue
%
N
on
-e
ve
nt
s
co
rr
ec
tly
re
cl
as
sif
ie
d
N
on
-
ev
en
t
P-
V
al
ue
O
ve
ra
ll 
C
oh
or
t
(n
=9
71
5)
FR
S 
+ 
CA
C
0.
58
96
6
0.
52
51
–0
.6
54
2
<
0.
00
01
29
%
<
0.
00
01
30
%
<
0.
00
01
N
CE
P 
A
TP
III
 +
0.
57
96
6
0.
51
49
–0
.6
44
4
<
0.
00
01
28
%
<
0.
00
01
30
%
<
0.
00
01
CA
C
Lo
w
ca
rd
io
va
sc
ul
ar
ri
sk
FR
S 
+ 
CA
C
0.
52
56
1
0.
39
61
–0
.6
55
1
<
0.
00
01
12
%
0.
07
41
%
<
0.
00
01
N
CE
P 
A
TP
 II
I +
0.
49
96
7
0.
38
78
–0
.6
11
6
<
0.
00
01
13
%
0.
02
37
%
<
0.
00
01
CA
C
In
te
rm
ed
ia
te
ca
rd
io
va
sc
ul
ar
ri
sk
FR
S 
+ 
CA
C
0.
46
41
7
0.
36
11
–0
.5
67
2
<
0.
00
01
23
%
<
0.
00
01
23
%
<
0.
00
01
N
CE
P 
A
TP
 II
I +
0.
51
54
4
0.
39
55
–0
.6
35
4
<
0.
00
01
28
%
<
0.
00
01
23
%
<
0.
00
01
CA
C
H
ig
h
ca
rd
io
va
sc
ul
ar
ri
sk
FR
S 
+ 
CA
C
0.
58
34
7
0.
47
09
–0
.6
96
1
<
0.
00
01
40
%
<
0.
00
01
18
%
<
0.
00
01
N
CE
P 
A
TP
 II
I +
0.
55
95
6
0.
44
94
–0
.6
69
8
<
0.
00
01
37
%
<
0.
00
01
19
%
<
0.
00
01
CA
C
A
bb
re
vi
at
io
ns
: N
RI
, n
et
 re
cl
as
sif
ic
at
io
n 
im
pr
ov
em
en
t; 
CA
C,
 c
or
on
ar
y 
ar
te
ry
 c
al
ci
um
; F
RS
, F
ra
m
in
gh
am
 R
isk
 S
co
re
;2
3  
N
CE
P 
A
TP
 II
I, 
N
at
io
na
l C
ho
le
ste
ro
l E
du
ca
tio
n 
Pr
og
ra
m
 A
du
lt 
Tr
ea
tm
en
t P
an
el
 
II
I.3
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2016 August 01.
